117976-89-3

Usage

Uses

Used in Pharmaceutical Industry:
Rabeprazole is used as a therapeutic agent for treating hyperacidity. It is effective in healing gastrointestinal ulcers, managing gastroesophageal reflux disease (GERD), and treating hypersecretory disorders, providing relief to patients suffering from these conditions.
Brand Name:
Rabeprazole is marketed under the brand name Aciphex by Eisai Medical Research, making it easily recognizable and accessible for those in need of its therapeutic benefits.

Dosage

Rabeprazole is usually taken once a day. Follow all directions on the prescription label and read all dosing instructions or instruction sheets. Use the medication exactly as directed.Rabeprazole is only suitable for short-term use, usually 4 to 8 weeks. If you need additional treatment time, your doctor may recommend a second course of treatment.

InChI:InChI=1/C11H16ClNO2/c1-9-10(8-12)13-5-4-11(9)15-7-3-6-14-2/h4-5H,3,6-8H2,1-2H3

Synthetic route

2,3-dimethyl-4-(3-methoxy-propoxy)pyridine (1080503-70-3) + (-)-menthyl 2-benzimidazolylsulphinate (1080503-68-9) → rabeprazole (117976-89-3)

Conditions	Yield
Stage #1: 2,3-dimethyl-4-(3-methoxy-propoxy)pyridine With n-butyllithium In tetrahydrofuran at -90 - -80℃; Stage #2: (-)-menthyl 2-benzimidazolylsulphinate In tetrahydrofuran at -80 - -20℃;	90%

rabeprazole sulfide (117977-21-6) → rabeprazole (117976-89-3)

Conditions	Yield
With sodium hydroxide; dihydrogen peroxide; sodium tungstate In methanol; water at 20℃; for 0.666667h; Product distribution / selectivity;	88%
With dihydrogen peroxide; sodium carbonate; sodium tungstate In methanol; water at 20℃; for 0.666667h; Product distribution / selectivity;	86.8%
With sodium hypochlorite; sodium hydroxide In water; acetonitrile Flow reactor;	85.1%

rabeprazole sulfide (117977-21-6) → rabeprazole (117976-89-3) + LY 307640 sulfone (117976-47-3)

Conditions	Yield
With sodium hydroxide; N-chloro-succinimide; water In acetonitrile at 0 - 5℃; for 2h; Product distribution / selectivity;	A 75% B 0.1%
With 3-chloro-benzenecarboperoxoic acid In dichloromethane at 20℃; for 1h; Product distribution / selectivity;	A 57% B 0.5%
With sodium hypochlorite; water In dichloromethane at 0 - 5℃; for 3 - 6h; Product distribution / selectivity;	A 52% B 0.5%

2-[4-(3-methoxypropoxy)-3-methyl-1-oxypyridin-2-yl-methylsulfinyl]-1H-benzimidazole sodium salt → rabeprazole (117976-89-3)

Conditions	Yield
With methanesulfonyl chloride; N-ethyl-N,N-diisopropylamine In acetonitrile at -10℃; for 6h; Product distribution / selectivity;	70%
With methanesulfonyl chloride; N-ethyl-N,N-diisopropylamine In acetonitrile at -10℃; for 6h; Product distribution / selectivity;	70%
With methanesulfonyl chloride; triethylamine In dichloromethane at -10℃; Product distribution / selectivity;
Stage #1: 2-[4-(3-methoxypropoxy)-3-methyl-1-oxypyridin-2-yl-methylsulfinyl]-1H-benzimidazole sodium salt With methanesulfonyl chloride; triethylamine In dichloromethane at -10℃; Stage #2: With water In dichloromethane Product distribution / selectivity;

2,3-dimethyl-4-nitropyridine N-oxide (37699-43-7) + methoxypropanol (1589-49-7) + Benzimidazol-2-thiol (134469-07-1) → 2-[(RS)-[(4-chloro-3-methylpyridin-2-yl)methyl]sulfinyl]-1H-benzimidazole + 2-[[(RS)-(1H-benzimidazol-2-yl)sulfinyl]methyl]-4-(3-methoxypropoxy)-3-methylpyridine 1-oxide (924663-38-7) + 2-[(RS)-[(4-methoxy-3-methylpyridin-2-yl)methyl]sulfinyl]-1H-benzimidazole (102804-77-3) + rabeprazole (117976-89-3)

Conditions	Yield
Multistep reaction. Further byproducts given;

2-[[(4-(3-methoxypropoxy)-3-methyl-pyridin-2-yl-1-oxide)methyl]sulfanyl]-1H-benzoimidazole (924663-40-1) → rabeprazole (117976-89-3)

Conditions	Yield
With lithium carbonate; ruthenium trichloride; sodium vanadate In acetonitrile for 2h; Heating / reflux;	5 %Chromat.
With sodium vanadate; lithium carbonate; ruthenium trichloride In acetonitrile for 2h; Heating / reflux;

Diethyl tartrate (408332-88-7) + rabeprazole sulfide (117977-21-6) → rabeprazole (117976-89-3)

Conditions	Yield
With N-ethyl-N,N-diisopropylamine; isopropylbenzene hydroperoxide; titanium(IV) isopropylate In water; toluene	1.1 g (49%)

diethyl (2S,3S)-tartrate (13811-71-7) + rabeprazole sulfide (117977-21-6) → rabeprazole (117976-89-3)

Conditions	Yield
With N-ethyl-N,N-diisopropylamine; isopropylbenzene hydroperoxide; titanium(IV) isopropylate In water; toluene	1.36 g (60%)

3-chloro-benzenecarboperoxoic acid (937-14-4) + rabeprazole sulfide (117977-21-6) → rabeprazole (117976-89-3)

Conditions	Yield
Stage #1: 3-chloro-benzenecarboperoxoic acid; rabeprazole sulfide In sodium hydroxide; diethyl ether; dichloromethane at -10℃; for 1.08333h; Stage #2: With triethylamine In diethyl ether; dichloromethane at 0 - 20℃;

2-[[(RS)-(1H-benzimidazol-2-yl)sulfinyl]methyl]-4-(3-methoxypropoxy)-3-methylpyridine 1-oxide (924663-38-7) → rabeprazole (117976-89-3)

Conditions	Yield
Stage #1: 2-[[(RS)-(1H-benzimidazol-2-yl)sulfinyl]methyl]-4-(3-methoxypropoxy)-3-methylpyridine 1-oxide With methanol; sodium methylate; ruthenium trichloride; N,N,N,N,-tetramethylethylenediamine at 50℃; for 10h; Stage #2: With acetic acid; sodium sulfite In water pH=6 - 7; Product distribution / selectivity;

N,N'-thiodimorpholine (5038-11-9) + 2-[[[4-[3-methoxypropoxy]-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole N-oxide → rabeprazole (117976-89-3)

Conditions	Yield
With ammonium acetate; sodium hydroxide; chloro-trimethyl-silane; sodium hydrogencarbonate In methanol; ethanol; dichloromethane; water	0.34 g (79%)

2-chloromethyl-4-(3-methoxy propyloxy)-3-methyl pyridine (117977-20-5) → rabeprazole (117976-89-3)

Conditions	Yield
Multi-step reaction with 2 steps 1.1: sodium hydroxide / water; ethanol / 25 - 30 °C 1.2: 25 - 30 °C 2.1: sodium hydroxide; sodium hypochlorite / water; acetonitrile / -8 - -2 °C View Scheme

2-hydroxymethyl-4-(methoxypropoxy)-3-methylpyridine hydrochloride (675198-19-3) → rabeprazole (117976-89-3)

Conditions	Yield
Multi-step reaction with 3 steps 1.1: thionyl chloride / dichloromethane / -10 - -5 °C 2.1: sodium hydroxide / water; ethanol / 25 - 30 °C 2.2: 25 - 30 °C 3.1: sodium hydroxide; sodium hypochlorite / water; acetonitrile / -8 - -2 °C View Scheme

2-hydroxymethyl-4-(3-methoxy propoxy)-3-methyl pyridine (118175-10-3) → rabeprazole (117976-89-3)

Conditions	Yield
Multi-step reaction with 2 steps 1: triphenylphosphine; diethylazodicarboxylate / tetrahydrofuran / 0 - 10 °C 2: sodium hydroxide; sodium hypochlorite / acetonitrile; water / 2 h / 0 - 5 °C View Scheme

Benzimidazol-2-thiol (134469-07-1) → rabeprazole (117976-89-3)

Conditions	Yield
Multi-step reaction with 2 steps 1: triphenylphosphine; diethylazodicarboxylate / tetrahydrofuran / 0 - 10 °C 2: sodium hydroxide; sodium hypochlorite / acetonitrile; water / 2 h / 0 - 5 °C View Scheme

C13H19NO5 → rabeprazole (117976-89-3)

Conditions	Yield
Multi-step reaction with 3 steps 1: sodium hydroxide 2: sodium hydride 3: 3-chloro-benzenecarboperoxoic acid View Scheme

rabeprazole (117976-89-3) → Rabeprazole sodium (117976-90-6)

Conditions	Yield
With sodium hydroxide In ethanol Product distribution / selectivity;	100%
With sodium hydroxide In water Product distribution / selectivity;	100%
With sodium carbonate; 2-fluoro-3-chloro-5-(trifluoromethyl)pyridine In ethanol at 35 - 40℃; for 2h; pH=9; Reagent/catalyst; Solvent;	98%

rabeprazole (117976-89-3) + LY 307640 sulfone (117976-47-3) → rabeprazol sulphone sodium salt + Rabeprazole sodium (117976-90-6)

Conditions	Yield
With sodium hydroxide In methanol at 0 - 50℃; for 4 - 5h; Product distribution / selectivity;	A 0.2% B 95%

rabeprazole (117976-89-3) → sodium 2-[2-[[(4-methoxypropoxy-3-methyl) pyridin-2-yl]methanesulfinyl]benzimidazole-1-sulfonyl]benzenesulfonate (519183-08-5)

Conditions	Yield
	92%

2-[p-(chlorosulfonyl)phenoxy]acetamide (69986-21-6) + rabeprazole (117976-89-3) → 2-(4-{[2-({[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl}sulfinyl)benzimidazol-1-yl]sulfonyl}phenoxy)acetamide (259183-37-4)

Conditions	Yield
Inert atmosphere; Basic conditions;	92%

Cyclopentamine (1003-03-8) + rabeprazole (117976-89-3) → 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole, cyclopentylamine salt

Conditions	Yield
In acetonitrile Product distribution / selectivity;	90.3%
In isopropyl alcohol Product distribution / selectivity;	88.9%
In ethyl acetate Product distribution / selectivity;	86.4%
In toluene at 55℃; Product distribution / selectivity;	80%

2-[p-(chlorosulfonyl)phenoxy]-N-(2-pyridyl)acetamide (259183-87-4) + rabeprazole (117976-89-3) → 2-(4-{[2-({[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl}sulfinyl)benzimidazol-1-yl]sulfonyl}phenoxy)-N-(2-pyridyl)acetamide (259183-27-2)

Conditions	Yield
Inert atmosphere; Basic conditions;	88%

SEC-BUTYLAMINE (33966-50-6) + rabeprazole (117976-89-3) → 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methysulfinyl]-1H-benzimidazole, sec-butylamine salt

Conditions	Yield
In acetonitrile Product distribution / selectivity;	87.1%
In ethyl acetate at 55℃; Product distribution / selectivity;	86.9%

isopropylamine (75-31-0) + rabeprazole (117976-89-3) → 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-vl}methylsulfinyl]-1H-benzimidazole, isopropylamine salt

Conditions	Yield
In acetonitrile Product distribution / selectivity;	83%
In acetonitrile at 55℃; Product distribution / selectivity;	82.7%
In ethyl acetate at 55℃; Product distribution / selectivity;	75.3%
In tetrahydrofuran Product distribution / selectivity;	75.6%

rabeprazole (117976-89-3) → 2-[(4-(3-methoxypropoxy)-3-methyl-pyridin-2-yl-1-oxide)methylsulfonyl]-1H-benzoimidazole

Conditions	Yield
With 3-chloro-benzenecarboperoxoic acid In methanol; chloroform at -10 - -5℃;	80%

2-Carbamoylmethoxy-4-chlorosulfonylphenoxyacetamide (519183-15-4) + rabeprazole (117976-89-3) → 2-(2-carbamoylmethoxy-4-{2-[4-(3-methoxypropoxy)-3-methylpyridin-2-ylmethylsulfinyl]benzimidazole-1-sulfonyl}phenoxy)acetamide (519183-09-6)

Conditions	Yield
Inert atmosphere; Basic conditions;	79%
With triethylamine In dichloromethane

2-chloromethyl-4-(3-methoxypropoxy)-3-methylpyridine hydrochloride + rabeprazole (117976-89-3) → 2-[([4-(3-methoxypropoxy)-3-methyl]pyridinyl)methyl]sulfinyl-1-[([4-(3-methoxypropoxy)-3-methyl]pyridinyl)methyl]-1H-benzimidazole (935260-92-7)

Conditions	Yield
With sodium hydroxide In water at 25 - 75℃;	78%

4-(4-morpholinyl)benzenesulfonyl chloride (125393-22-8) + rabeprazole (117976-89-3) → 1-[4-(morpholin-4-yl)phenylsulfonyl]-2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole (259183-28-3)

Conditions	Yield
Inert atmosphere; Basic conditions;	78%

[2-(morpholin-4-yl)ethoxy]benzene-4-sulfonyl chloride (259183-84-1) + rabeprazole (117976-89-3) → 1-[{2-(morpholin-4-yl)ethoxy}phenyl-4-sulfonyl]-2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole (259183-29-4)

Conditions	Yield
Inert atmosphere; Basic conditions;	77%

N-[4-(chlorosulfonyl)phenyl]urea (40685-78-7) + rabeprazole (117976-89-3) → N-(4-{[2-({[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl}sulfinyl)benzimidazol-1-yl]sulfonyl}phenyl)urea (259183-25-0)

Conditions	Yield
Inert atmosphere; Basic conditions;	74%

N-(carbamoylmethyl)-2-[4-(chlorosulfonyl)phenoxy]acetamide (259183-90-9) + rabeprazole (117976-89-3) → N-(carbamoylmethyl)-2-(4-{[2-({[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl}sulfinyl)benzimidazol-1-yl]sulfonyl}phenoxy)acetamide (259183-47-6)

Conditions	Yield
Inert atmosphere; Basic conditions;	72%

[2-{2-(morpholin-4-yl)ethoxy}ethoxy]benzene-4-sulfonyl chloride (259183-85-2) + rabeprazole (117976-89-3) → 1-[[2-{2-(morpholin-4-yl)ethoxy}ethoxy]phenyl-4-sulfonyl]-2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole (259183-43-2)

Conditions	Yield
Inert atmosphere; Basic conditions;	56%

(S)-[1,1']-binaphthalenyl-2,2'-diol (18531-99-2) + rabeprazole (117976-89-3) → (S)-rabeprazole-(S)-(-)-BINOL complex

Conditions	Yield
In cyclohexane; toluene at 3 - 52℃; for 1.25 - 1.75h;	55.6%

dimethyl sulfate (77-78-1) + rabeprazole (117976-89-3) → N1-methyl rabeprazole

Conditions	Yield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In dichloromethane at 20℃;

rabeprazole (117976-89-3) → 2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methylsulfinyl]-1H-benzimidazole hemicalcium

Conditions	Yield
Stage #1: rabeprazole With sodium hydroxide In methanol at 15 - 20℃; for 0.25h; Stage #2: With calcium acetate In methanol at 20℃; for 14.5h;

2-[(chlorocarbonyl)(methyl)amino]ethyl ethyl carbonate (635751-00-7) + rabeprazole (117976-89-3) → ethyl 2-[[[2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]carbonyl](methyl)amino]ethyl carbonate

Conditions	Yield
With triethylamine; dmap In tetrahydrofuran at 60℃; for 17h;
With dmap; triethylamine In tetrahydrofuran at 60℃; for 17h;	0.44 g

2-[(chlorocarbonyl) (phenyl)amino]ethyl acetate (635751-44-9) + rabeprazole (117976-89-3) → 2-[[[2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]carbonyl](phenyl)amino]ethyl acetate

Conditions	Yield
With triethylamine; dmap In tetrahydrofuran at 60℃; for 16h;
With dmap; triethylamine In tetrahydrofuran at 60℃; for 16h;	0.93 g

Upstream product

• 37699-43-7 2,3-dimethyl-4-nitropyridine N-oxide 
• 1589-49-7 methoxypropanol 
• 134469-07-1 Benzimidazol-2-thiol 
• 117977-21-6 rabeprazole sulfide 
• 408332-88-7 Diethyl tartrate 
• 13811-71-7 diethyl (2S,3S)-tartrate 
• 937-14-4 3-chloro-benzenecarboperoxoic acid 
• 5038-11-9 N,N'-thiodimorpholine 
• 118175-10-3 2-hydroxymethyl-4-(3-methoxy propoxy)-3-methyl pyridine 
• 675198-19-3 [4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanol hydrochloride 
• 117977-20-5 2-chloromethyl-4-(3-methoxy propyloxy)-3-methyl pyridine 
• 1080503-70-3 2,3-dimethyl-4-(3-methoxy-propoxy)pyridine 
• 1080503-68-9 (-)-menthyl 2-benzimidazolylsulphinate 
• 924663-38-7 2-[[(RS)-(1H-benzimidazol-2-yl)sulfinyl]methyl]-4-(3-methoxypropoxy)-3-methylpyridine 1-oxide 

Downstream Products

• 117976-90-6 Rabeprazole sodium 
• 519183-08-5 sodium 2-[2-[[(4-methoxypropoxy-3-methyl) pyridin-2-yl]methanesulfinyl]benzimidazole-1-sulfonyl]benzenesulfonate 
• 259183-28-3 1-[4-(morpholin-4-yl)phenylsulfonyl]-2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole 
• 259183-25-0 N-(4-{[2-({[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl}sulfinyl)benzimidazol-1-yl]sulfonyl}phenyl)urea 
• 259183-37-4 2-(4-{[2-({[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl}sulfinyl)benzimidazol-1-yl]sulfonyl}phenoxy)acetamide 
• 259183-43-2 1-[[2-{2-(morpholin-4-yl)ethoxy}ethoxy]phenyl-4-sulfonyl]-2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole 
• 259183-29-4 1-[{2-(morpholin-4-yl)ethoxy}phenyl-4-sulfonyl]-2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole 
• 259183-27-2 2-(4-{[2-({[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl}sulfinyl)benzimidazol-1-yl]sulfonyl}phenoxy)-N-(2-pyridyl)acetamide 
• 259183-47-6 N-(carbamoylmethyl)-2-(4-{[2-({[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl}sulfinyl)benzimidazol-1-yl]sulfonyl}phenoxy)acetamide 
• 924663-37-6 2-[(4-(3-methoxypropoxy)-3-methyl-pyridin-2-yl-1-oxide)methylsulfonyl]-1H-benzoimidazole 
• 519183-09-6 2-(2-carbamoylmethoxy-4-{2-[4-(3-methoxypropoxy)-3-methylpyridin-2-ylmethylsulfinyl]benzimidazole-1-sulfonyl}phenoxy)acetamide 

Relevant academic research and scientific papers

An improved process for the production of rabeprazole sodium substantially free from the impurities

The present work details the journey towards development of a simple and cost-viable process for large-scale synthesis of rabeprazole sodium substantially free from the impurities. The detailed study of different parameters affecting the quality and yield percentage of the compound has been presented. Yield is increased from 40% (reported process) to 75% with the improved process at sulfoxidation stage.

Method for preparing benzimidazole proton pump inhibitor

The invention provides a novel method for preparing a benzimidazole proton pump inhibitor, and belongs to the field of medicine synthesis. According to the method provided by the invention, a complexformed by using graphene oxide and a transition metal salt is used as a catalyst, and the corresponding benzimidazole proton pump inhibitor is obtained through oxidizing a thioether by an oxidizing agent under an alkaline condition in an organic solvent. The method has the advantages of mild reaction condition, high yield, environmental friendliness, and less impurity, the catalyst can be recycled, and the method is suitable for industrial production.

INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF

The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

Preparation method for key intermediate rabeprazole thioether

The invention discloses a preparation method for rabeprazole thioether 2-[[[4-(3- methoxypropoxy)-3-methylpyridin-2-yl] methyl] sulfo]-1H-benzimidazole. By using Mitsunobu reaction, the rabeprazole thioether is prepared from rabeprazole oxhydryl in one-step synthesis way without chlorination reaction. In the reaction process, the high-corrosive chloride agent, such as, thionyl chloride, is not used, so that the violent corrosion of the reaction to the device is obviously reduced, and meanwhile, the reaction yield is obviously increased due to the shortened reaction step. According to the invention, the process is simple, the reaction condition is mild, the corrosion to the device is small, the yield is higher (70%-80%) and the method is suitable for industrial production.

Method for preparing optically-pure Rabeprazole

The invention discloses a method for preparing optically-pure Rabeprazole. The method is used for preparing a chiral 2-[[4-(3-methoxypropoxy)-3-methylpyrid-2-yl]methylsulfinyl]-1H-benzimidazole compound (Rabeprazole), which is present in a single-enantiomer form or rich-enantiomer form, in an enantioselective manner. The same effects, i.e., identical enantioselectivity and conversion ratio can be achieved through complexing a tartaric acid diamide ligand and titanium and adding an organic-base additive or not in the presence of water. The invention further provides a method for preparing a sodium salt from the obtained Rabeprazole.

A right-handed sodium rebeilazole for method for the synthesis of

The invention relates to a method for synthesizing rabeprazole sodium. The method comprises the following steps: performing asymmetric oxidation on raw materials with cumyl hydroperoxide, extracting through a sodium hydroxide solution, neutralizing to the pH value of 9.7 by using acid, separating out high-purity white rabeprazole sodium solids, filtering without drying, directly adding a wet sample into a mixed system of sodium hydroxide and dichloromethane and alkane solvent while stirring for reacting at the temperature of 0-30 DEG C for 3-5 hours, filtering, and drying, thereby obtaining the white rabeprazole sodium solids. According to the method disclosed by the invention, the operating steps are simplified, the yield is improved, the rabeprazole is prevented from being dried and heated, unknown impurities generated by heat instability are reduced, and use of an organic solvent is reduced.

PROCESS FOR THE PREPARATION OF RABEPRAZOLE

The present invention provides a compound of Formula III, process of its preparation and its use as a reference marker or as a reference standard. The present invention further provides a process for the preparation of rabeprazole, a salt or a solvate thereof. The invention also provides a chromatographic method for testing the purity of rabeprazole, a salt or a solvate thereof.

Application of continuous flow micromixing reactor technology for synthesis of benzimidazole drugs

Synthesis of pharmaceutically active compounds by employing continuous flow micromixing reactor technology is an interesting research area. In this article we describe the synthesis of benzimidazole core drugs, such as lansoprazole (1a), pantaprazole (1b), and rabeprazole (1c) by using a continuous flow micromixing reactor technology. A key feature of the sulfoxidation includes the decreasing the reaction time from 3 h to ～1 s to minimize the formation of sulfone impurities and improve the yields.

NEW CRYSTALLINE FORMS OF RABEPRAZOLE SODIUM

The present invention relates to crystalline forms of rabeprazole sodium and processes for their preparation. The invention also relates to pharmaceutical compositions comprising rabeprazole sodium.

PROCESS FOR PURIFICATION OF RABEPRAZOLE SODIUM

There is provided a process for preparing amorphous rabeprazole sodium. Thus, for example, sodium hydroxide was dissolved in methanol. Rabeprazole was added to the solution and stirred at 25 - 35°C for 1 hour. Methanol was distilled off from the reaction mass, dichloromethane was added to the residual mass and the contents were stirred to obtain solution. The solution was added to cyclohexane. The contents were stirred at 25 - 35°C for 30 minutes, centrifuged the material and washed at 60 - 65°C to obtain amorphous rabeprazole sodium.